Abstract
Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.
| Original language | English |
|---|---|
| Pages (from-to) | S4-S7 |
| Journal | International Heart Journal |
| Volume | 56 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Update on medical treatment of patients with eisenmenger syndrome. / Fukushima, Hiroyuki.
In: International Heart Journal, Vol. 56, 2015, p. S4-S7.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Update on medical treatment of patients with eisenmenger syndrome
AU - Fukushima, Hiroyuki
PY - 2015
Y1 - 2015
N2 - Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.
AB - Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.
UR - http://www.scopus.com/inward/record.url?scp=84929942740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929942740&partnerID=8YFLogxK
U2 - 10.1536/ihj.14-347
DO - 10.1536/ihj.14-347
M3 - Article
VL - 56
SP - S4-S7
JO - International Heart Journal
JF - International Heart Journal
SN - 1349-2365
ER -